ReviewJournal of oral and maxillofacial pathology : JOMFP
Immunohistochemical expression of inflammasome-related proteins in head and neck squamous cell carcinoma tissues-A systematic review.
Review in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammasomes are multiprotein complexes that play a crucial role in cancer pathogenesis, including in head and neck squamous cell carcinoma (HNSCC), by regulating inflammation, immune responses, and tumour progression. This systematic review aimed to synthesize current evidence on the immunohistochemical (IHC) expression of inflammasome-related proteins in human HNSCC tissues. Methodology: A comprehensive search of PubMed, Scopus, Web of Science, LILACS, and Google Scholar was conducted up to 31 May 2025, following PRISMA 2020 guidelines and after prior registration in PROSPERO. Studies were included if they evaluated inflammasome-related proteins, such as NLRP3, ASC, caspase-1, and IL-1β, using IHC in human HNSCC tissues. Results: Sixteen studies were eligible, with sample sizes ranging from 7 to 176. Risk of bias was assessed using a modified QUIN tool, which revealed some methodological limitations, particularly with scoring consistency, blinding, and antibody validation. NLRP3 was the most consistently overexpressed marker, frequently associated with advanced tumour stage, poor prognosis, and therapy resistance. Other proteins, including IL-1β, ASC, and caspase-1, also demonstrated elevated expression and were linked to inflammation and metastatic features. Gasdermin E was associated with favourable clinical outcomes and improved chemotherapy response. Certainty of evidence, assessed using the GRADE approach, was moderate for NLRP3 but low for other markers. Significant heterogeneity in IHC protocols and a lack of standardized scoring limited cross-study comparability. Conclusion: Overall, inflammasome-related proteins, especially NLRP3, appear to be key contributors to HNSCC progression and may hold potential as prognostic biomarkers or therapeutic targets. Systematic review registration: PROSPERO CRD42023453852.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.